Better leads,
fewer cycles
Prioritize high-performing candidates before entering the lab
Generate, optimize and screen - all in one single platform
ConvergeAB™ is trained on over 1 trillion natural protein tokens, including 7 million antibody sequences, 3 million antibody–antigen pairs, and 100,000 fully characterized antibodies. This foundation enables affinity maturation, developability optimization, humanization, patent escape and IP expansion, and candidate screening across IgG, ScFv, and VHH formats.
Input
Input
You provide the biological elements: a mandatory protein sequence defining the final product, and optional regulatory regions. The promoter controls gene expression strength, while the 5’ and 3’ UTRs influence mRNA stability, translation efficiency, and overall protein yield, all of which can be optimized.
2nd
Predictors
Predictors
Each predictor scores generated antibodies on key drug-development properties: correct heavy/light chain pairing, binding strength, off-target risk, cellular expression, solubility, thermostability, aggregation risk, and self-association, ensuring selected candidates are potent, stable, and manufacturable.
2nd
Output
Output
After generating and scoring many designs, the system selects a small set of high-confidence antibody candidates that bind strongly, demonstrate developability and manufacturability, and carry lower risk of failure—ready for experimental validation in the lab.
ConvergeAB™ is trained on over 1 trillion natural protein tokens, including 7 million antibody sequences, 3 million antibody–antigen pairs, and 100,000 fully characterized antibodies. This foundation enables affinity maturation, developability optimization, humanization, patent escape and IP expansion, and candidate screening across IgG, ScFv, and VHH formats.
Converge data sources
Training dataset
Customer private instance
